breast carcinoma
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1.Female patients with cT1-2N0M0 breast cancer; 2.Age = 18 years; 3.Patients scheduled to undergo intraoperative sentinel lymph node biopsy (SLNB); 4.Patients who voluntarily participate in the study and have provided written informed consent;
Exclusion criteria
Exclusion criteria: 1.History of prior ipsilateral breast or axillary surgery, radiotherapy, or receipt of neoadjuvant chemotherapy; 2.Patients with bilateral breast cancer; 3.Patients unable to undergo the complete ultrasound examination or needle biopsy; 4.Pregnant patients or those with a known allergy to ultrasound contrast agents; 5.Patients with incomplete clinical-pathological data or ultrasound image;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Diagnostic concordance rate of CEUS-guided biopsy of sentinel lymph nodes;Accuracy of percutaneous contrast-enhanced ultrasound (CEUS) lymphography in localizing sentinel lymph nodes (SLNs);Diagnostic performance of intravenous contrast-enhanced ultrasound (CEUS) for characterizing sentinel lymph node metastasis; | — |
Secondary
| Measure | Time frame |
|---|---|
| Contrast-enhanced ultrasound enhancement patterns of sentinel lymph nodes; | — |
Countries
China
Contacts
Cancer Hospital, Chinese Academy of Medical Sciences